Jubilant Pharmova Ltd

NSE: JUBLPHARMA · Pharmaceuticals · sector

₹937.00NSE close 2026-10-26

Key numbers

Market cap₹14,805 cr

Price₹937.00

52w high / low₹1,185 / ₹786

P/E42.1xSector median 27.9x

P/B2.1xSector median 2.9x

Book value₹448.9

Dividend yield0.54%Sector median 0.48%

ROE5.3%Sector median 11.7%

ROCE7.4%Sector median 12.3%

OPM13.5%Sector median 14.0%

Debt / equity0.45xSector median 0.16x

EV/EBITDA14.5xSector median 18.6x

Interest cover3.5x

Current ratio1.62x

Sales growth 3y+9.6%Sector median +9.6%

Profit growth 3y–Sector median +13.3%

PEG–

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹1,268 cr vs borrowings ₹3,220 cr (FY26): borrowings are higher by ₹1,952 cr.
Operating profit covered interest 3.5x in the last 12 months.
6.51% of the promoters' shares are pledged (3.1% of all shares).
Operating cash flow was below net profit in 0 of the last 5 years.
Revenue was higher than a year earlier in 4 of the last 4 quarters.
Other income was 21% of net profit in the last 12 months.
Dividend paid in 5 of the last 5 financial years.
Price ₹937.00 on 2026-10-26: -20.9% from the 52-week high, +19.2% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹1,238.10 · low ₹816.20

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	1,752	1,822	1,929	1,901	1,966	2,122	2,290	2,229
EBITDA	275	268	342	290	336	250	326	248
OPM %	15.7%	14.7%	17.7%	15.2%	17.1%	11.8%	14.2%	11.1%
Other income	22	9	12	12	10	20	24	20
Net profit	103	101	154	103	120	56	119	56
EPS (₹)	6.47	6.37	9.71	6.49	7.59	3.52	7.55	3.57
Revenue YoY					+12.2%	+16.5%	+18.7%	+17.3%
Profit YoY					+17.0%	-44.6%	-22.3%	-45.1%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	6,059	6,282	6,703	7,234	8,280	8,608
EBITDA	1,085	719	732	1,533	1,201	1,159
Net profit	414	-61	77	839	398	352
EPS (₹)	26.00	-3.83	4.87	52.99	25.15	22.23
Revenue growth		+3.7%	+6.7%	+7.9%	+14.4%	+16.3%
Profit growth		-114.7%	–	+988.7%	-52.5%	-23.5%
Dividend / share (₹)	5.00	5.00	5.00	5.00	5.00

Compounded growth	3 years	5 years	Last 12 months
Sales	+9.6%	+6.3%	+16.3%
Net profit	–	-13.8%	-23.5%
EPS	–	-13.7%	–
Share price	–	-11.4% (2y)	-18.7%

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	5,399	5,434	6,255	7,093
Borrowings	–	3,410	3,414	2,437	3,220
Cash & equivalents	–	1,014	957	1,089	1,268
Total assets	–	11,157	11,548	12,756	15,523
Fixed assets	–	2,298	2,158	2,132	3,510
Capital work in progress	–	773	1,252	2,715	2,962
Investments	–	33	34	36	61
Receivables	–	961	916	892	1,070
Inventory	–	1,381	1,290	1,129	1,232
Payables	–	821	856	1,005	1,234

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	838	661	971	1,072	1,227
Cash from investing	-380	-544	-608	488	-1,260
Cash from financing	-33	-157	-432	-1,453	95
Capex	600	814	898	1,116	1,449
Free cash flow	238	-154	74	-44	-222

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	-1.1%	1.4%	13.4%	5.6%
ROCE %	–	2.3%	4.7%	14.1%	8.0%
Debtor days	–	56	50	45	47
Inventory days	–	268	220	178	170
Payable days	–	160	146	158	170
Cash conversion cycle (days)	–	164	124	65	47
Working capital days	–	116	95	68	69

Shareholding

Holder	% (2026-09-30)
Promoters	47.68%
FIIs	15.38%
DIIs	13.02%
of which Mutual funds	9.42%
of which Insurance	1.07%
Public (non-institutions)	23.38%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	50.68%	50.68%	47.68%	47.68%	47.68%	47.68%	47.68%	47.68%

Promoter group	%
SPB Trustee Company PVT Ltd	20.08%
HSB Trustee Company PVT Ltd	19.00%
Miller Holdings PTE Ltd	3.28%
MAV Management Advisors LLP	3.15%
Nikita Resources Private Limited	0.97%
Priyavrat Bhartia	0.88%
Hari Shanker Bhartia	0.23%
Shamit Bhartia	0.08%
Kavita Bhartia	0.01%
Jaytee Private Limited	0.00%
Jubilant Enpro Private Limited	0.00%
VAM Holdings Limited	0.00%
Jubilant Consumer Private Limited	0.00%
Jubilant Advisors LLP	0.00%
Shyam Sunder Bhartia	0.00%

Public holders above 1%	%
Bandhan Small CAP Fund	4.01%
Rekha Jhunjhunwala	3.28%
Rekha Jhunjhunwala	3.15%
Government Pension Fund Global	2.81%
East Bridge Capital Master Fund I Ltd	2.53%
Theleme India Master Fund Limited	2.02%
Quant Mutual Fund - Quant Small CAP Fund	1.85%
Kotak Mahindra Trustee Co Ltd A/C Kotak Multicap Fund	1.68%
Investor Education and Protection Fund Authority Ministry of Corporate Affairs	1.24%
Abakkus Emerging Opportunities Fund-1	1.15%
SBI Life Insurance Co. Ltd	1.07%

82,602 shareholders. Pledged: 6.51% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
JUBLPHARMA	₹14,805 cr	42.1x	2.1x	5.3%	7.4%	13.5%	+9.6%	0.54%

All 185 companies in Pharmaceuticals →

Business segments (FY26)

Segment	Revenue	Share	EBIT	Margin
Radiopharma	₹3,690 cr	69.4%	₹360 cr	9.8%
Allergy Immunotherapy	₹796 cr	15.0%	₹272 cr	34.1%
Generics	₹774 cr	14.5%	₹28 cr	3.6%
Unallocable corporate	₹58 cr	1.1%	₹0 cr	0.0%
Proprietary Novel Drugs	₹0 cr	–	₹-19 cr	–

Dividends & corporate actions

Ex-date	Action	Detail
2026-07-24	Dividend	Dividend - Rs 5 Per Share
2025-07-25	Dividend	Dividend - Rs 5 Per Share
2024-08-02	Dividend	Dividend - Rs 5 Per Share
2023-08-10	Dividend	Dividend - Rs 5 Per Share
2022-08-11	Dividend	Dividend - Rs 5 Per Share
2021-08-05	Dividend	Dividend - Rs 5 Per Share
2021-02-04	Restructuring	Demerger
2020-03-09	Dividend	Interim Dividend - Rs 5 Per Share
2019-09-12	Dividend	Annual General Meeting/Dividend - Rs 4.50 Per Share
2018-09-12	Dividend	Annual General Meeting/Dividend Rs 3 Per Share
2017-08-16	Dividend	Annual General Meeting/ Dividend - Rs 3/- Per Share
2016-08-18	Dividend	Annual General Meeting/ Dividend - Rs 3/- Per Share
2015-08-20	Dividend	Annual General Meeting/ Dividend - Rs 3/- Per Share
2014-08-21	Dividend	Annual General Meeting / Dividend - Rs 3/- Per Share
2013-08-14	Dividend	Annual General Meeting And Dividend Rs.3/- Per Share
2012-08-14	Dividend	Annual General Meeting/ Dividend Rs 3 Per Share
2011-08-10	Dividend	Annual General Meeting And Dividend Rs.2/- Per Share
2010-11-25	Restructuring	Scheme Of Demerger
2010-09-17	Dividend	Annual General Meeting And Dividend Rs.2/- Per Share
2009-06-29	Dividend	Dividend-Rs.1.50 Pr Share

Documents

Links go to the original files on the exchange website.

About the company

Radiopharma: Radiopharma
Allergy Immunotherapy: Allergy Immunotherapy
Contract Development and Manufacturing Organisation - Sterile Injectables: Contract Development and Manufacturing Organisation - Sterile Injectables
Generics: Generics
Contract Research, Development and Manufacturing Organisation: Contract Research, Development and Manufacturing Organisation
Proprietary Novel Drugs: Proprietary Novel Drugs
Management Services: Management Services


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	JUBLPHARMA
BSE code	530019
ISIN	INE700A01033
Face value	₹1.0
Incorporated	1978-06-21
Website	www.jubilantpharmova.com
Plants (India / abroad)	2 / 3

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.